Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agilon Health (AGL) Cash & Equivalents (2020 - 2025)

Agilon Health's Cash & Equivalents history spans 6 years, with the latest figure at $173.7 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 7.71% year-over-year to $173.7 million; the TTM value through Dec 2025 reached $173.7 million, down 7.71%, while the annual FY2025 figure was $173.7 million, 7.71% down from the prior year.
  • Cash & Equivalents reached $173.7 million in Q4 2025 per AGL's latest filing, up from $171.7 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $1.1 billion in Q2 2021 to a low of $105.3 million in Q1 2021.
  • Average Cash & Equivalents over 5 years is $405.8 million, with a median of $181.0 million recorded in 2024.
  • Peak YoY movement for Cash & Equivalents: surged 873.86% in 2021, then tumbled 76.88% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $1.0 billion in 2021, then crashed by 55.26% to $465.3 million in 2022, then crashed by 76.88% to $107.6 million in 2023, then soared by 74.98% to $188.2 million in 2024, then dropped by 7.71% to $173.7 million in 2025.
  • Per Business Quant, the three most recent readings for AGL's Cash & Equivalents are $173.7 million (Q4 2025), $171.7 million (Q3 2025), and $171.4 million (Q2 2025).